Lineage Cell Therapeutics CEO Secures Nearly 3 Million‑Share Zero‑Cost Option, Signaling Long‑Term Confidence in Biotech Growth
Lineage Cell Therapeutics CEO Brian Culley receives a zero‑priced, 3.25 million‑share option grant—signaling insider confidence and a bullish outlook for investors.
- Lineage Cell Therapeutics Inc
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read